The founders Niels C. Riedemann and Renfeng Guo share a joint several years lasting research history focusing on the role of C5a and C5aR in life threatening infectious and non-infectious inflammatory diseases. Their work largely contributed to the understanding of the role of C5a and the molecular mechanisms involved in disease progression. It was the meaning of the target C5a in its key involvement in most inflammatory innate immune responses that led to their decision to found a company and to be the first to bring a targeted anti-C5a approach into clinical application.
2007 Foundation of InflaRx GmbH in Jena
InflaRx GmbH was founded in December 2007 in Jena, Germany an internationally recognized acute care clinical trial hub. InflaRx developed close collaborative ties with the Department of Anesthesiology and Intensive Care Therapy at the Jena University Medical Center, where Niels held the position as Vice Director of Intensive Care Therapy for several years. InflaRx thereby built an in depth in-house expertise in the acute care and inflammatory disease field.
Simultaneously, CSO Renfeng expanded its collaborations with the Beijing Institute of Sciences and other renowned Chinese immunologists, allowing InflaRx to conduct top-tier immunological research abroad. These collaborations lead for example to the ground-breaking work on the role of C5a in different types of lung-injury in non-human primates and other discoveries.
2008 A Break-through Discovery
In 2008, InflaRx made a break-through discovery allowing to generate monoclonal anti-C5a antibodies which were highly selective (not blocking the terminal membrane attack complex) while at the same time being extremely potent regarding their immunological blocking activity. The InflaRx's discoveries were filed as patent applications globally and have been issued as patents in various countries.
2011 First Clinical Trial Phase I
In 2011, InflaRx started a clinical phase I trial with an anti-C5a antibody, demonstrating that IFX-1 was safe and well tolerated.
2014 Successful Generation of IFX-2
In 2014, InflaRx was able to successfully generate IFX-2, a follow-on molecule of IFX-1, which is planned to cover development in more chronic inflammatory diseases and IFX-3, a first bi-specific molecule with a broad range of application possibilities in inflammation related diseases.
2015 Phase II Trial Completed
In 2015, InflaRx completed a phase IIa trial with an anti-C5a inhibitory approach. This first of its kind clinical acute care trial was conducted in patients suffering from live-threatening infections and early organ dysfunction. This trial validated the InflaRx IFX-1 technology, demonstrating that C5a can be effectively controlled and blocked by IFX-1 in this setting.
2017 Phase IIa Hidradenitis Suppurativa
In 2017 InflaRx completed a first clinical phase IIa open label single center study in Hidradenitis Suppurativa (HS) patients demonstrating a clinical response rate using the Hidradenitis Clinical Response Score (HISCR) of 83% at the end of the trial observation period in 12 Hurley Stage III severe patients.
2017 InflaRx US Nasdaq IPO after Crossover Financing Round
In Nov. 2017, InflaRx conducted its successful US IPO with a total gross proceeds of USD 106 million on the US Nasdaq global select market after closing a crossover financing round with high class US investors exactly 2 weeks before start of the US roadshow with a total proceeds of USD 55 million (USD 30 million primary and USD 25 million secondary component).
2018 Follow-on Transaction
In April 2018 InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first day shareholders of InflaRx.
InflaRx today comprises a growing team of highly skilled researchers, clinicians and business experts that are driven and united by the vision to deliver game changing drugs fighting inflammatory diseases of highest unmet medical need. Our team strives to transform the anti-inflammatory drug space in different disease settings.
“We believe that more than 18 years of in depth research and focus on C5a as target by the founders and our team as well as the discovery of our unique technology allowing us to specifically block and control C5a have allowed us to take a global lead position in this area. Our vision is that this may bring benefit to many patients globally suffering from various inflammatory diseases” states Niels Riedemann, founder and CEO of InflaRx.